Economy06:00 · Aug 13

Merit CEO Alon Tal Clarifies No Management Role in Channel 13 Amid Ownership Deal

Calcalist
Translated & summarized from Calcalist by baba
The story · English

Alon Tal, CEO and founder of the philanthropic investment fund Merit, has emerged as a key figure in the recent acquisition of Israeli Channel 13 by Waze founders Assaf Rappaport and Yinon Kostika. Despite the high-profile nature of the deal, Tal emphasizes that Merit currently holds no direct management involvement in Channel 13, as the transaction awaits final approval from the Second Authority for Television and Radio. The acquisition includes a commitment to invest approximately $100 million in content and digital platforms, with Tal expected to represent the owners on the channel's board but not engage in daily operations.

Tal, who has a background in financial management and philanthropy, explains that the purchase was structured through Merit for efficiency and personal connections rather than as a social project. He stresses that the channel is part of Merit’s investment portfolio aimed at improving its value, with any profits intended to support social initiatives. Tal rejects claims that the acquisition is politically motivated, stating, "We have no agenda and will not be involved in politics or content decisions."

The deal has faced regulatory scrutiny amid political controversy, including attempts by the government to alter the composition of the Second Authority’s council to influence approval. Despite this, Tal is confident the transaction will be authorized, highlighting the importance of stable financial backing to attract talent and improve Channel 13’s low ratings compared to competitors.

Beyond media, Tal’s career spans algorithmic trading, family wealth management, and philanthropy. He founded Merit in 2021 to provide transparent and efficient frameworks for donors, managing assets exceeding one billion shekels and supporting projects from medical treatments to diaspora relations. Tal also invests in biotech innovations aiming to revolutionize personalized medicine by enabling hospitals to produce gene therapies on-site, drastically reducing costs.

While the ownership transfer is pending regulatory clearance, Channel 13 has already seen significant management changes, including new appointments in executive roles. Questions remain about who currently holds decision-making authority during this interim period. Tal reiterates that Merit’s role is financial and strategic, not operational, as the channel navigates this transitional phase.

Read the original at Calcalist
Open the live terminal